BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BioCentury | Jan 5, 2018
Clinical News

Actinium reports Phase II data for Actimab-A in AML

Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) reported preliminary data from 13 evaluable patients ages 60 and older with newly diagnosed acute myelogenous leukemia (AML) who were unable to tolerate induction therapy in the Phase II portion of...
BioCentury | Jul 28, 2017
Financial News

Follow-on roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
BioCentury | Feb 9, 2017
Clinical News

Actimab-M: Ph I started

Actinium began an open-label, U.S. Phase I trial to evaluate IV Actimab-M on day 1 of each 42-day cycle in about 12 patients. The starting dose of Actimab-M is 0.5 µCi/kg, which may be increased...
BioCentury | Oct 3, 2016
Clinical News

Actimab-A: Phase II started

Actinium began an open-label, U.S. Phase II trial to evaluate 2 uCi/kg/fraction doses of Actimab-A given at day 1 and 7 in about 53 patients ages >60. Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y. Product:...
BioCentury | Dec 14, 2015
Clinical News

Actimab-A: Additional Phase I/II data

Data from 14 previously untreated AML patients ages >=60 in the Phase I portion of an open-label, U.S. Phase I/II trial showed that 0.5, 1, 1.5 and 2 uCi/kg/fraction doses of Actimab-A plus low-dose cytarabine...
BioCentury | Jun 22, 2015
Clinical News

Actimab-A: Additional Phase I/II data

Additional data from 12 previously untreated AML patients >=60 in cohorts 1-3 of an open-label, U.S. Phase I/II trial showed that Actimab-A plus low-dose cytarabine led to 2 cases of complete remission with different degrees...
BioCentury | Jun 8, 2015
Finance

ASCO's early returns

While discussions about value and incremental data from late-stage checkpoint inhibitors dominated this year's American Society of Clinical Oncology meeting in Chicago, it's clear that investors also were on the lookout for - and willing to...
BioCentury | Jan 5, 2015
Clinical News

Actimab-A regulatory update

FDA granted Orphan Drug designation to Actimab-A from Actinium to treat acute myelogenous leukemia (AML) in patients ages =60. The product -- actinium-225 attached to the anti- CD33 mAb lintuzumab (HuM195) -- is in Phase...
BioCentury | Nov 24, 2014
Clinical News

Actimab-A: Interim Phase I/II data

Interim data from 9 evaluable AML patients ages =60 in an open-label, U.S. Phase I/II trial showed that Actimab-A plus low-dose cytarabine led to a median overall survival (OS) of 5.4 months. In 7 of...
Items per page:
1 - 10 of 17